Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03397394 · FLOW

Participant flow

Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma · Source last updated 2023-06-09

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups
  1. description
    Patients with HRD status unknown who received continuous dosing with rucaparib 600 mg twice a day (BID) in 28-day cycles. Patients whose tumor genome-wide LOH was not tested or not determined were considered HRD unknown.
    id
    FG000
    title
    HRD Unknown
  2. description
    Patients with HRD status negative who received continuous dosing with rucaparib 600 mg twice a day (BID) in 28-day cycles. Patients whose tumor had genome-wide LOH \< 10% were considered HRD-negative.
    id
    FG001
    title
    HRD Negative
  3. description
    Patients with HRD status positive who received continuous dosing with rucaparib 600 mg twice a day (BID) in 28-day cycles. Patients whose tumor had genome-wide LOH ≥ 10% were considered HRD-positive.
    id
    FG002
    title
    HRD Positive
periods
  1. milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        47
      2. group Id
        FG001
        num Subjects
        30
      3. group Id
        FG002
        num Subjects
        20
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        47
      2. group Id
        FG001
        num Subjects
        30
      3. group Id
        FG002
        num Subjects
        20
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        0
      2. group Id
        FG001
        num Subjects
        0
      3. group Id
        FG002
        num Subjects
        0
      type
      NOT COMPLETED
    title
    Overall Study
recruitment Details
97 subjects were recruited from 40 sites across 6 countries.
Complete source fields
groups
  1. description
    Patients with HRD status unknown who received continuous dosing with rucaparib 600 mg twice a day (BID) in 28-day cycles. Patients whose tumor genome-wide LOH was not tested or not determined were considered HRD unknown.
    id
    FG000
    title
    HRD Unknown
  2. description
    Patients with HRD status negative who received continuous dosing with rucaparib 600 mg twice a day (BID) in 28-day cycles. Patients whose tumor had genome-wide LOH \< 10% were considered HRD-negative.
    id
    FG001
    title
    HRD Negative
  3. description
    Patients with HRD status positive who received continuous dosing with rucaparib 600 mg twice a day (BID) in 28-day cycles. Patients whose tumor had genome-wide LOH ≥ 10% were considered HRD-positive.
    id
    FG002
    title
    HRD Positive
periods
  1. milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        47
      2. group Id
        FG001
        num Subjects
        30
      3. group Id
        FG002
        num Subjects
        20
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        47
      2. group Id
        FG001
        num Subjects
        30
      3. group Id
        FG002
        num Subjects
        20
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        0
      2. group Id
        FG001
        num Subjects
        0
      3. group Id
        FG002
        num Subjects
        0
      type
      NOT COMPLETED
    title
    Overall Study
recruitment Details
97 subjects were recruited from 40 sites across 6 countries.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice